Alcon Stock Rated Buy by BTIG Following TRYPTYR Approval

On May 30, BTIG analysts reaffirmed their Buy rating and $99 price target for Alcon Inc. (NYSE:ALC) following the FDA’s approval of TRYPTYR for the treatment of dry eye disease (DED). Previously known as AR-15512, the novel eye drop is scheduled to make its commercial debut in the United States around the third quarter of 2025, with plans to extend to other markets later.

With the clearance of TRYPTYR, Alcon Inc. (NYSE:ALC), which had a minor presence in the DED pharmaceutical industry prior to purchasing EYSUVIS assets from Kala Pharmaceuticals in May 2022, has taken a major step forward. According to company management, TRYPTYR’s peak sales are expected to be between $250 million and $400 million. The FDA’s labeling, which covers both DED symptoms and indicators, would determine this range.

Alcon Inc. (NYSE:ALC) intends to expand its eye drop product sales team in order to support the launch of TRYPTYR. However, the company expects TRYPTYR’s revenue contribution to be limited at first. However, the company expects gains from a full year of sales in fiscal year 2027 to be more much substantial.

While we acknowledge the potential of ALC to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ALC and that has 100x upside potential, check out our report about the cheapest AI stock.

Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.